Background-Our laboratory has previously shown that ␦-opioid receptors are involved in the cardioprotective effect of ischemic preconditioning in the rat heart. However, this class of receptors consists of two subtypes, ␦ 1 and ␦ 2 , and -or -opioid receptors may also exist in the heart. Therefore, the purpose of the present study was to test the hypothesis that ischemic preconditioning is mediated through stimulation of one or both ␦-opioid receptor subtypes. Methods and Results-Anesthetized, open chest, male Wistar rats were assigned to 1 of 14 groups. All animals were subjected to 30 minutes of occlusion and 2 hours of reperfusion. Ischemic preconditioning was elicited by three 5-minute occlusion periods interspersed with 5 minutes of reperfusion. Two doses of 7-benzylidenenaltrexone (BNTX; 1 and 3 mg/kg IV), a selective ␦ 1 -opioid receptor antagonist, or naltriben (NTB; 1 and 3 mg/kg IV), a selective ␦ 2 -opioid receptor antagonist, were given before ischemic preconditioning. To test for a role of -opioid receptors, rats were pretreated with ␤-funaltrexamine (␤-FNA; 15 mg/kg SC), an irreversible -opioid receptor antagonist, 24 hours before ischemic preconditioning or given the -opioid receptor agonist D-Ala, 2 N-Me-Phe, 4 glycerol 5 -enkephalin (DAMGO) as three 5-minute infusions (1, 10, and 100 g/kg per infusion IV, respectively) interspersed with 5-minute drug-free periods before the prolonged ischemic and reperfusion periods (lowDAMGO, medDAMGO, and hiDAMGO, respectively). The involvement of -opioid receptors was tested by administering one of two doses of nor-binaltorphimine (nor-BNI; 1 and 5 mg/kg IV) before ischemic preconditioning. Infarct size (IS) as a percent of the area at risk (AAR) was measured by triphenyltetrazolium stain. Ischemic preconditioning markedly reduced IS/AAR (14Ϯ4%, PϽ.05) compared with control (55Ϯ4%). NTB, ␤-FNA, and nor-BNI were unable to block the cardioprotective effect of ischemic preconditioning. In addition, DAMGO had no effect on IS/AAR. However, the high dose of BNTX (3 mg/kg IV) significantly attenuated the cardioprotective effect of ischemic preconditioning (39Ϯ5%; PϽ.05 versus control and ischemic preconditioning). Conclusions-These results indicate that ␦ 1 -opioid receptors play an important role in the cardioprotective effect of ischemic preconditioning in the rat heart. (Circulation. 1998;97:1282-1289.)
T he idea of multiple opioid receptors is an accepted concept, and a number of subtypes for each class of opioid receptors has been identified. [1] [2] [3] [4] Through biochemical and pharmacological methods, the -, ␦-, and -opioid receptors have been characterized. 3, 5 Pharmacologically, it is well known that ␦-opioid receptors consist of two subtypes, ␦ 1 and ␦ 2 . [6] [7] [8] Opioid receptor activation has been implicated to elicit a protective effect during situations of stress produced by hypoxia, ischemia, cold, or acidic environments, 9 -20 and the ␦-opioid receptor has been demonstrated to play a major role in this protection. [13] [14] [15] 18 Mayfield and D'Alecy 14, 15 showed, using DPDPE (selective ␦ 1 -opioid receptor agonist) and BNTX (selective ␦ 1 -opioid receptor antagonist), that the ␦ 1 -opioid receptor mediated the adaption or increased survival time of mice to hypoxic environments. Furthermore, Chien et al 13 demonstrated that the time before organ transplantation was increased significantly from a 6-hour window to a 48-hour window after the administration of a synthetic ␦-opioid receptor agonist, DADLE. Recently, our laboratory showed that ␦-opioid receptors were involved in the cardioprotective effect of ischemic preconditioning (PC) in the intact rat heart. 18 We demonstrated that administration of naltrindole, a nonselective ␦-opioid receptor antagonist, attenuated the cardioprotective effect of ischemic PC and morphine. 18 However, the role of the specific ␦-opioid receptor subtype (␦ 1 and ␦ 2 ) as well as a role for -and -opioid receptors in the cardioprotective effect of ischemic PC remains unknown. Therefore, the focus of the present study was to determine the role of these four opioid receptor subtypes in mediating the cardioprotective effect of ischemic PC in the intact rat heart.
Methods
This study was performed in accordance with the guidelines of the Animal Care Committee of the Medical College of Wisconsin, which is accredited by the American Association of Laboratory Animal Care.
General Surgical Preparation
Male Wistar rats weighing 350 to 450 g were used. The rats were anesthetized by intraperitoneal administration with the long-acting thiobutabarbital inactin (100 mg/kg IV). A tracheotomy was performed and the rat was intubated with a cannula connected to a rodent ventilator (model 683, Harvard Apparatus) and ventilated with room air at 65 to 70 breaths/min. Atelectasis was prevented by maintaining a positive end-expiratory pressure of 5 to 10 mm of H 2 O. Arterial pH, PCO 2 , and PO 2 were monitored at baseline, at 15 minutes of occlusion, and at 15, 60, and 120 minutes of reperfusion by a blood gas analyzer (AVL 995, Automatic Blood Gas System) and maintained within a normal physiological range (pH 7.35 to 7.45; PCO 2 25 to 40 mm Hg; PO 2 80 to 110 mm Hg) by adjusting the respiratory rate and/or tidal volume (2 to 4 mL/100 g). Body temperature was monitored (Yellow Springs Instruments, TeleThermometer) and maintained at 37Ϯ1°C (meanϮSEM) by use of a heating pad.
The right carotid artery was cannulated to measure blood pressure and heart rate with a Gould PE50 or Gould PE23 pressure transducer, which was connected to a Grass (model 7) polygraph. The right jugular vein was cannulated to infuse saline or drugs. A left thoracotomy was performed Ϸ15 mm from the sternum to expose the heart at the fifth intercostal space. The pericardium was removed and the left atrial appendage was moved to reveal the location of the left coronary artery. The vein descending along the septum of the heart was used as the marker for the left coronary artery. A ligature (6 -0 prolene), along with a snare occluder, was placed around the vein and left coronary artery close to the place of origin. After surgical preparation, the rat was allowed to stabilize for 15 minutes before the various interventions. ]-enkephalin (DPDPE) were purchased from Research Biochemicals International. 7-benzylidenenaltrexone (BNTX), naltriben (NTB), and ␤-funaltrexamine (␤-FNA) were generously donated as gifts from Dr Hiroshi Nagase, Toray Industries, Inc, Kanagawa, Japan. D-Ala, -enkephalin (DAMGO) was purchased from Bachem Bioscience, Inc. 2,3,5-triphenyltetrazolium chloride (TTC) was purchased from Sigma Chemical Co. Inactin, NTB, and DAMGO were dissolved in 0.9% saline. BNTX and DPDPE were dissolved in distilled water and brought up to volume with saline. ␤-FNA, U-50488H, and nor-BNI were dissolved in distilled water. TTC was dissolved in a 100 mmol/L phosphate buffer.
Study Groups and Experimental Protocols
All protocols contained control (group I) and three 5-minute ischemic PC (group II) groups. The control group was subjected to 30 minutes of occlusion and 2 hours of reperfusion. Ischemic PC was elicited by three 5-minute occlusion periods interspersed with 5 minutes of reperfusion before the prolonged occlusion and reperfusion periods. Fig 1 represents the experimental protocol designed to demonstrate the specific ␦ (␦ 1 or ␦ 2 ) opioid receptor involved in the cardioprotective effect of ischemic PC. In group III, BNTX (3 mg/kg IV) was given 10 minutes before the long occlusion period in nonpreconditioned animals. Groups IV and V showed a dose-response effect of BNTX to antagonize ischemic PC (1 and 3 mg/kg IV; lowBNTXϩPC and hiBNTXϩPC, respectively). In group VI, NTB (1 mg/kg IV) was administered 10 minutes before the 30 minutes of occlusion in nonpreconditioned animals. In groups VII and VIII, NTB (1 and 3 mg/kg IV, respectively) was given as a bolus 10 minutes before ischemic PC or as an infusion starting 60 minutes before ischemic PC and continuing for 50 minutes (lowNTBϩPC and hiNTBϩPC, respectively). A slow infusion of the high dose of NTB was necessary because this dose produced a marked hypotensive effect when rapidly administered.
Because -and -opioid receptors have been implicated in many cardiovascular physiological and pathophysiological responses, [21] [22] [23] [24] several pharmacological antagonists and one agonist were used to determine if these two opioid receptors were involved in ischemic PC in the intact rat heart (Fig 2) . In group IX, animals were pretreated 24 hours before ischemic PC with ␤-funaltrexamine (␤-FNA; 15 mg/kg SC), an irreversible -opioid receptor antagonist (␤-FNAϩPC). To test if stimulating the -opioid receptor mimicked ischemic PC, groups X through XII consisted of three 5-minute infusions (1, 10, and 100 g/kg per infusion IV, respectively) of DAMGO, a selective -opioid receptor agonist, interspersed with 5-minute drug-free periods before the prolonged ischemic and reperfusion periods (lowDAMGO, medDAMGO, hiDAMGO, respectively). Last, to test if -opioid receptors mediated the cardioprotective effect of ischemic PC, a dose-response effect of nor-binaltorphimine (nor-BNI), a -opioid receptor antagonist, was studied. In groups XIII (low nor-BNIϩPC) and XIV (hi nor-BNIϩPC), nor-BNI (1 and 5 mg/kg IV, respectively) was given 15 minutes before ischemic PC. In previous studies, we have shown that saline or distilled water had no effect on infarct size in rat hearts. 16, 17 
Specificity of the Opioid Receptor Agonist and Antagonists
To demonstrate that the effect of the antagonists and agonists occurred at a specific opioid receptor, BNTX, and NTB, the ␦ 1 -and ␦ 2 -opioid receptor antagonists, respectively, ␤-FNA, the irreversible -opioid receptor antagonist, nor-BNI, the -opioid receptor antagonist, Figure 1 . Protocol used to determine which ␦-opioid receptor subtype mediates the cardioprotective effect of ischemic preconditioning (PC). Groups consist of I, control (CON); II, ischemic PC elicited by three 5-minute occlusion periods interspersed with 5 minutes of reperfusion; III, BNTX (3 mg/kg IV), a selective ␦ 1 -opioid receptor antagonist, given 10 minutes before the 30 minutes of occlusion; IV, lowBNTXϩPC, BNTX (1 mg/kg IV) given 10 minutes before ischemic PC; V, hiBNTXϩPC, BNTX (3 mg/kg IV) given 10 minutes before ischemic PC; VI, NTB, naltriben (1 mg/kg IV), a ␦ 2 -opioid receptor antagonist, given 10 minutes before the 30 minutes of occlusion; VII, lowNTBϩPC, NTB (1 mg/kg IV) given 10 minutes before ischemic PC; and VIII, hiNTBϩPC, naltriben (3 mg/kg IV) infused for 50 minutes before ischemic PC.
DAMGO, the -opioid receptor agonist, DPDPE, the ␦-opioid receptor agonist, and U-50488H, the -opioid receptor agonist, were used. DAMGO produced a transient hypotensive effect during infusion of the three doses (1, 10, and 100 g/kg IV) studied. Therefore, animals that were pretreated with ␤-FNA (group 9 from Fig 2) were subjected to a dose response of DAMGO (3, 30, and 300 g/kg IV) before ischemic PC to test the specificity of ␤-FNA for the -opioid receptor. Similarly, a dose response of DAMGO (3, 30, and 300 g/kg IV) was studied with BNTX or NTB (groups III and VI from Fig 1) in which either ␦-opioid receptor antagonist was given and then a DAMGO dose response was performed before the long occlusion period to demonstrate the lack of effect of BNTX and NTB for the -receptor and their specificity for the ␦ 1 -(BNTX) and ␦ 2 -(NTB) opioid receptor.
In addition, specificity of the ␦ 1 -, ␦ 2 -, and -antagonists to their respective opioid receptors was further demonstrated with a ␦-and -opioid receptor agonist. A dose response of DPDPE (1, 3, and 10 mg/kg IV), the ␦-opioid receptor agonist, was performed and a transient decrease in blood pressure was observed. BNTX (3 mg/kg IV), the ␦ 1 -opioid receptor antagonist, was given 10 minutes before the next DPDPE dose response. Similarly, a dose response of U-50488H (1, 5, and 10 mg/kg IV), the -opioid receptor agonist, was performed followed by the administration of nor-BNI (5 mg/kg IV), the -opioid receptor antagonist, 15 minutes before the next U-50488H dose response.
Pretreatment for 24 hours with ␤-FNA resulted in a complete blockade of the vascular response to DAMGO, whereas neither BNTX nor NTB had any effect on the response to DAMGO (data not shown). The decrease in blood pressure caused by DPDPE was antagonized by BNTX but not by NTB (data not shown). In addition, hypotensive responses to U-50488H were blocked by nor-BNI (data not shown). These data demonstrate that the doses of opioid antagonists used are specific for their respective receptors.
Determination of Infarct Size
After each experiment, the left coronary artery was reoccluded and Patent blue dye was injected into the venous catheter to stain the normally perfused region of the heart. The rat was euthanized with 15% KCl through the arterial catheter. The heart was excised and the left ventricle removed and sliced into five cross-sectional pieces. This procedure allowed for visualization of the normal, nonischemic region and the area at risk (AAR). The AAR was separated from the normal area with the use of a dissecting scope (Cambridge Instruments). Both tissue regions (nonischemic and AAR) were incubated at 37°C for 15 minutes in a 1% 2,3,5-triphenyltetrazolium stain in 100 mmol/L phosphate buffer (pH 7.4). TTC was used as an indicator to separate out viable and nonviable tissue. 25 The tissue was stored overnight in a 10% formaldehyde solution. The following day, the infarcted tissue was separated from the AAR by use of the dissecting scope. The different regions (nonischemic, AAR, and infarct) were determined by gravimetry, and infarct size (IS) was calculated as a % of the AAR (IS/AAR).
Exclusion Criteria
A total of 107 animals were assigned to the present study. Animals were excluded from the study because of unacceptable blood gases, intractable ventricular fibrillation (VF), or hypotension (mean arterial blood pressure Ͻ30 mm Hg). Three animals in the control group, two in the ischemic PC group, two animals in the hiBNTXϩPC group, one in the hiDAMGO group, and four animals in the ␤-FNAϩPC group were excluded because of intractable ventricular fibrillation. In addition, three animals in the hiNTBϩPC group and one animal in the low nor-BNIϩPC group were excluded because of hypotension. A total of 91 animals completed the study.
Statistical Analysis of the Data
All values are expressed as meanϮSEM. One-way ANOVA was used to determine differences among groups for IS and AAR. Differences between groups in hemodynamics at various time points were compared by use of two-way ANOVA for time and treatment with repeated measures and Fisher's least significant difference test if significant F ratios were obtained. Statistical differences were considered significant if the probability value was Ͻ.05.
Results
Hemodynamics Tables 1 and 2 summarize the meanϮSEM values for the hemodynamic parameters of heart rate (HR), mean arterial blood pressure (MBP), and rate-pressure product (RPP) analyzed at baseline, 30 minutes of occlusion, and 2 hours of reperfusion. In Table 1 , HR, MBP, and RPP at baseline were not significantly different among the groups. However, at 30 minutes of occlusion, the MBP in the lowBNTXϩPC group was significantly higher compared with control, but by 2 hours of reperfusion, no differences in MBP were found between groups. In addition, RPP at 30 minutes of occlusion was significantly higher in the ischemic PC, BNTX, lowBNTXϩPC, and hiBNTXϩPC groups; however, the RPP at 2 hours of reperfusion was not significantly different in any of these groups. The HR in the NTB group was significantly lower at 2 hours of reperfusion, but there was no significant difference in MBP or RPP. Table 2 shows that the baseline HR in the ischemic PC group was significantly lower than control; however, HR in this group was not significantly different from control at 30 minutes of occlusion or 2 hours of reperfusion. The hi-DAMGO group had a significantly lower HR compared with control at 2 hours of reperfusion. The medDAMGO and ␤-FNAϩPC groups had a significantly lower MBP at 30 minutes of occlusion and 2 hours of reperfusion. In addition, MBP at 2 hours of reperfusion was significantly lower in the hiDAMGO and low nor-BNIϩPC groups. RPP at 30 minutes of occlusion was significantly lower in the medDAMGO and ␤-FNAϩPC groups. However, there were no significant differences in RPP among the groups at 2 hours of reperfusion. Table 3 . The LV and AAR weights were not significantly different between groups. Infarct size was significantly smaller in the ischemic PC, lowBNTXϩPC, and both NTBϩPC groups. The IS/AAR data for the individual rat hearts are depicted in Fig  3 as well as the meanϮSEM for each group. The control group had an average IS/AAR of 53.2Ϯ2.9%. Ischemic PC markedly reduced infarct size to 14.1Ϯ5.1% (PϽ.05 versus control). The low dose of the selective ␦ 1 -receptor antagonist BNTX (1 mg/kg IV) did not attenuate the effect of ischemic PC (19.0Ϯ3.4%; PϽ.05), whereas the high dose of BNTX (3 mg/kg IV) significantly attenuated the cardioprotective effect of ischemic PC (38.7Ϯ5.4%; PϽ.05 versus control and ischemic PC). Similarly, a dose response to NTB, a ␦ 2 -opioid receptor antagonist, was performed. Neither dose (1 and 3 mg/kg IV) of NTB inhibited HR indicates heart rate (beats/min); MBP, mean arterial blood pressure (mm Hg); RPP, rate-pressure product (mm Hg/min per 1000); Ischemic PC, three 5-minute ischemic periods; BNTX (3 mg/kg IV), a selective ␦ 1 -opioid receptor antagonist, given 10 minutes before the 30-minute occlusion; lowBNTXϩIschemic PC, BNTX (1 mg/kg IV) given 10 minutes before ischemic PC; hiBNTXϩIschemic PC, BNTX (3 mg/kg IV) given 10 minutes before ischemic PC; NTB, naltriben (1 mg/kg IV), a selective ␦ 2 -opioid receptor antagonist, given 10 minutes before the 30-minute occlusion; lowNTBϩIschemic PC, naltriben (1 mg/kg IV) given 10 minutes before ischemic PC; and hiNTBϩIschemic PC, naltriben (3 mg/kg IV) infused for 60 minutes before ischemic PC.
Infarct Size and Area at Risk
Values given as meanϮSEM; *PϽ.05 vs control. HR indicates heart rate (beats/min); MBP, mean arterial blood pressure (mm Hg); RPP, rate-pressure product (mm Hg/min per 1000); Ischemic PC, three 5-minute ischemic periods; ␤-FNA, ␤-funaltrexamine (15 mg/kg SC, 24-hour pretreatment), irreversible -opioid receptor antagonist given before ischemic preconditioning (PC); lowDAMGO, three 5-minute DAMGO infusions (1 g/kg per infusion), -opioid receptor agonist; medDAMGO, three 5-minute DAMGO infusions (10 g/kg per infusion), -opioid receptor agonist; hiDAMGO, three 5-minute DAMGO infusions (100 g/kg per infusion), -opioid receptor agonist; lownorBNI, nor-binaltorphine (1 mg/kg IV) given 15 minutes before ischemic PC; and hinorBNI, nor-binaltorphine (5 mg/kg IV) given 15 minutes before ischemic PC (3ϫ100 g/kg per 5-minute infusion).
Values given as meanϮSEM; *PϽ.05 vs control.
the cardioprotective effect of ischemic PC (24.4Ϯ6.5% and 18.1Ϯ2.5%, respectively). BNTX or NTB alone had no effect on infarct size in nonpreconditioned groups.
-and -Opioid Receptors The results shown in Table 4 indicate that there were no significant differences in LV and AAR weights between the groups. Also, the results in Table 4 demonstrate that the IS weights in ischemic PC, ␤-FNAϩPC-treated animals, and low and hi nor-BNIϩPC groups were significantly lower compared with control. In addition, the results in Fig 4 show 
Discussion
The class of ␦-opioid receptors consists of two subtypes, ␦ 1 and ␦ 2 . [6] [7] [8] There are a number of pharmacological agents available to distinguish these two subtypes of ␦-opioid receptor. 5 BNTX, a nonpeptidic ␦ 1 -opioid receptor antagonist, and NTB, a nonpeptidic ␦ 2 -opioid receptor antagonist, were used in the present study to clarify the role of these two subtypes to mediate the cardioprotective effect of ischemic PC. A number of studies have demonstrated the selectivity and specificity of BNTX and NTB toward its respective opioid receptor. 26 -28 Dose responses of both BNTX and NTB were performed in the present study, and the results demonstrate that the high dose (3 mg/kg IV) of BNTX but not the low dose (1 mg/kg IV) partially abolished the protective effect of ischemic PC. Conversely, neither dose of NTB (1 or 3 mg/kg IV) blocked ischemic PC. Our results demonstrating that BNTX at the low dose (1 mg/kg) did not block the cardioprotective effect of ischemic PC confirm the results obtained by Mayfield and D'Alecy. 15 This group observed that 1 mg/kg of BNTX did not decrease the hypoxic survival time of mice; however, at a higher dose of BNTX (10 mg/kg), the hypoxic survival time was significantly decreased. 15 Similarly, we observed that the cardioprotective effect of ischemic PC in the rat was blocked at a higher dose of BNTX (3 mg/kg). BNTX (3 mg/kg IV) and NTB (1 mg/kg IV) in combination when given 10 minutes before ischemic PC did not have an additive effect to block the cardioprotective effect (data not shown). In fact, the IS/AAR observed when the combination of BNTX and NTB was given was no larger than the IS/AAR observed when BNTX alone was given before ischemic PC. This observation further suggests that ischemic PC in the rat heart is predominantly mediated by the ␦ 1 -opioid Figure 3 . Infarct sizes in rat hearts subjected to control (CON); ischemic preconditioning (PC) elicited by three 5-minute occlusion periods interspersed with 5 minutes of reperfusion; BNTX (3 mg/kg IV), a selective ␦ 1 -opioid receptor antagonist, given 10 minutes before the 30 minutes of occlusion; lowBNTXϩPC, BNTX (1 mg/kg IV) given 10 minutes before ischemic PC; hiBNTXϩPC, BNTX (3 mg/kg IV) given 10 minutes before ischemic PC; NTB, naltriben (1 mg/kg IV), a ␦ 2 -opioid receptor antagonist, given 10 minutes before the 30 minutes of occlusion; lowNTBϩPC, NTB (1 mg/kg IV) given 10 minutes before ischemic PC; and hiNTBϩPC, naltriben (3 mg/kg IV) infused for 50 minutes before ischemic PC. E, Infarct sizes from individual hearts; ⅷ, group mean infarct size; meanϮSEM, with *PϽ.05 vs control and * §PϽ.05 vs control and ischemic PC. Values given as meanϮSEM. There were no significant differences among the groups for the LV and AAR sizes. IS in PC, lowBNTXϩPC, low-and hiBNTXϩPC hearts showed a significant difference compared with control (*PϽ.05 vs control).
receptor. Overall, these data demonstrate that the ␦ 1 -opioid receptor is the important ␦-opioid receptor subtype involved in the cardioprotective effect of ischemic PC in the rat. Further studies with selective ␦ 1 -opioid receptor agonists are necessary to demonstrate that stimulating this ␦-opioid receptor produces a cardioprotective effect to reduce infarct size in the rat heart.
Involvement of -and -opioid receptors were studied with the use of the -receptor agonist DAMGO, the irreversible -receptor antagonist ␤-FNA, and the -receptor antagonist nor-BNI. Many studies have provided evidence that DAMGO and ␤-FNA are selective for the -opioid receptor, 29, 30 and nor-BNI is selective for -opioid receptors. 31, 32 We demonstrated that ␤-FNA (15 mg/kg SC) when administered 24 hours preceding ischemic PC did not block its cardioprotective effect. Similarly, DAMGO at any of the doses studied did not mimic the cardioprotection induced by brief periods of ischemia. Previously, we showed that morphine reduced infarct size and elicited a cardioprotective effect in the rat heart, indicating that this cardioprotection may involve -opioid receptors. 17 However, our laboratory recently showed that naltrindole, a nonselective ␦-opioid receptor antagonist, abolished the cardioprotective effect of morphine, demonstrating that its protection is mediated by a ␦-opioid receptor. 18 It is known that morphine has high affinity for the -opioid receptor; however, morphine has also been shown to interact with the ␦-and -opioid receptors. 3, 22, 33 In addition, a number of investigators have demonstrated that cross-talk can occur between -and ␦-opioid receptors. 34 -37 Therefore, we used a more selective -opioid receptor agonist, DAMGO, to further demonstrate and clarify the role, if any, of -opioid receptors in the cardioprotective effect of ischemic PC in the rat. The present results clearly suggest that the -opioid receptor does not mediate ischemic PC. The lack of -opioid receptor activity in the cardioprotective effect of ischemic PC has also been supported by a number of functional and receptor binding studies in ventricular myocytes, indicating an absence of this particular opioid receptor in this tissue. 33,38 -41 In addition, the hypoxic conditioning study by Mayfield and D'Alecy 15 showed that ␤-FNA (48-hour pretreatment with 1 to 20 mg/kg SC) did not decrease hypoxic survival time in mice, indicating that the -opioid receptor was not involved.
The role of -opioid receptors in the protective effect of ischemic PC was tested by the use of nor-BNI, a selective -opioid receptor antagonist. Two doses of nor-BNI (1 and 5 mg/kg IV) were tested. Neither dose of nor-BNI abolished ischemic PC, suggesting that -opioid receptors are not involved in cardioprotection in the rat. As with the BNTX and NTB combination, there was no additive effect to block ischemic PC in the rat when BNTX (3 mg/kg IV) and nor-BNI (1 mg/kg IV) were given together (data not shown). In support of the lack of involvement of the -opioid receptor in ischemic PC, Xia et al 42 demonstrated that antiarrhythmic effect of ischemic PC in the isolated rat heart may be due to a decreased affinity of -opioid and IS, infarct size in grams. Protocols are described in "Methods" and in footnote to Table 2 .
Values given as meanϮSEM. There were no significant differences among the groups for the LV and AAR sizes. IS in PC, ␤-FNA, low-and hinorBNI hearts showed a significant difference (*PϽ.05 vs control).
receptor binding by U69593, a highly selective -agonist, during reperfusion. Also, Mayfield and D'Alecy 15 were unable to decrease hypoxic survival time of mice with nor-BNI (1 to 20 mg/kg SC) when animals were subjected to hypoxic preconditioning. Furthermore, Niroomand et al 43 indicated that -opioid receptors may not be present on canine cardiac sarcolemma because the -agonist U50488H did not inhibit adenylate cyclase activity.
In summary, our results indicate that the beneficial effect of brief periods of ischemia are partially mediated by the ␦ 1 -opioid receptor. BNTX, the ␦ 1 -opioid receptor antagonist, attenuated the cardioprotection, whereas NTB, the ␦ 2 -opioid receptor antagonist, did not inhibit ischemic PC. Neithernor -opioid receptors seem to be involved in eliciting cardioprotection in the rat heart because antagonists to these two receptors did not prevent PC and DAMGO, a selective -opioid receptor agonist, did not mimic ischemic PC. Also, combinations of the ␦ 2 -or -antagonist with BNTX did not produce an additive inhibition of ischemic PC in comparison to the results with BNTX alone, suggesting that ischemic PC in the rat occurs primarily through activation of ␦ 1 -opioid receptors.
The results of this study suggest that there may be significant clinical potential for stimulating ␦ 1 -opioid receptors with regard to treating cardiac ischemia in patients with coronary artery disease; however, more studies need to be performed to demonstrate a universal role for ␦ 1 -opioid receptors in ischemic PC in all species. Opioids have been used clinically to manage pain after surgery. The demonstration that opioid receptors, most notably ␦ 1 , which not only have analgesic properties but may have the potential to protect the myocardium during cardiac surgical interventions, suggests a possible new pharmacological approach for the treatment of patients with acute myocardial infarction.
